// App-Quantinova.ai

4501 : Efficacy and safety of nivolumab monotherapy in metastatic urothelial cancer: Results from the phase I/II CheckMate 032 study.

Researchers

Presenter

  • Padmanee Sharma

Principal Investigators

  • Petri Bono

  • Joseph W. Kim

  • Pavlina Spiliopoulou

  • Emiliano Calvo

  • Rathi Narayana Pillai

  • Patrick Alexander Ott

  • Filippo G. De Braud

  • Michael A. Morse

  • Dung T Le

  • Dirk Jaeger

  • Emily Chan

  • Christopher T. Harbison

  • Chen-Sheng Lin

  • Marina Tschaika

  • Alex Azrilevich

  • Jonathan Rosenberg

Medical Centers

  • The University of Texas MD Anderson Cancer Canter, Houston, TX

  • Comprehensive Cancer Center, Helsinki University Hospital, Helsinki, Finland

  • Yale University-Yale Cancer Center, New Haven, CT

  • Beatson West of Scotland Cancer Centre, Glasgow, United Kingdom

  • START Department, Centro Integral Oncologico Clara Campal, Madrid, Spain

  • Winship Cancer Institute of Emory University, Atlanta, GA

  • Dana-Farber Cancer Institute, Boston, MA

  • Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy

  • Duke University Medical Center, Durham, NC

  • The Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD

  • National Center for Tumor Diseases, University of Heidelberg, Heidelberg, Germany

  • Vanderbilt University Medical Center, Nashville, TN

  • Bristol-Myers Sqiubb, Princeton, NJ

  • Memorial Sloan Kettering Cancer Center, Port Washington, NY

Locations

  • Finland

  • Italy

  • Spain

  • Germany

  • United Kingdom

  • United States

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

  • Urology

Disease

  • Advanced Urothelial Carcinoma

Biomarkers

  • Programmed death-ligand 1

Drug/Treatment

  • Nivolumab

Outcome

  • N/A

Study Design

  • N/A

Phase

  • I/II

Study Id's

  • NCT01928394

Sponsors

  • N/A

Result

  • Final

Copyright © 2026. QuantiNova All rights reserved